ICCC

$6.05

Post-MarketAs of Mar 17, 8:00 PM UTC

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$6.05
Potential Upside
5%
Whystock Fair Value$6.35
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastit...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$54.73M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.30
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-3.63%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
-

Recent News

GuruFocus.com
Mar 7, 2026

ImmuCell Corp (ICCC) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges

ImmuCell Corp (ICCC) reports improved profitability and gross margins, while addressing sales declines and strategic shifts for future growth.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 6, 2026

ImmuCell 2025 Net Loss Narrows Y/Y as Sales & Margins Improve

ICCC's 2025 sales rise 4.3% y/y, with the gross margin expanding sharply, helping narrow its annual net loss despite asset write-downs and strategic shifts.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
MarketBeat
Mar 6, 2026

ImmuCell Q4 Earnings Call Highlights

ImmuCell (NASDAQ:ICCC) executives used the company’s fourth-quarter and full-year 2025 earnings call to highlight a year of operational change, improved margins, and a strategic pivot toward expanding its First Defense calf scours prevention franchise while stepping away from investment in its Re-Ta

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Moby
Mar 5, 2026

ImmuCell Corporation Q4 2025 Earnings Call Summary

Moby summary of ImmuCell Corporation's Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Zacks
Jan 15, 2026

Niche Focus & Regulation Shape the Future of Healthcare Firms

CPIX, NAII and ICCC lean into specialization, compliance and targeted growth to thrive in the niche healthcare markets.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.